Diana Moss was quoted in the May 31, 2018 Bloomberg News story Bayer AG, Monsanto Co. Approval Hinges on Risky Innovation Fix.
But there is still inherent risk in betting that remedies fashioned by antitrust enforcers will ensure innovation. “The remedy raises significant issues of execution risk,” Diana Moss, president of the American Antitrust Institute, said in a press release May 29. Under the proposed remedy, BASF is expected to fully restore competition in an area in which it is not experienced, she said, making the Bayer-Monsanto remedy a “tall order.”
